ABSTRACT
INTRODUCTION: Epidermal growth factor receptor (EGFR) inhibition is an imperative therapeutic approach targeting various types of cancer including colorectal, lung, breast, and pancreatic cancer types. Moreover, cyclooxygenase-2 (COX-2) is frequently overexpressed in different types of cancers and has a role in the promotion of malignancy, apoptosis inhibition, and metastasis of tumor cells. Combination therapy has been emerged to improve the therapeutic benefit against cancer and curb intrinsic and acquired resistance. METHODS: Three semi-synthetic series of compounds (C1-4, P1-4, and G1-4) were prepared and evaluated biologically as potential dual epidermal growth factor receptor (EGFR) and COX-2 inhibitors. The main phenolic constituents of Amaranthus spinosus L. (p-coumaric, caffeic and gallic) acids have been isolated and subsequently subjected to diazo coupling with various amines to get novel three chemical scaffolds with potential anticancer activities. RESULTS: Compounds C4 and G4 showed superior inhibitory activity against EGFR (IC50: 0.9 and 0.5 µM, respectively) and displayed good COX-2 inhibition (IC50: 4.35 and 2.47 µM, respectively). Moreover, the final compounds were further evaluated for their cytotoxic activity against human colon cancer (HT-29), pancreatic cancer (PaCa-2), human malignant melanoma (A375), lung cancer (H-460), and pancreatic ductal cancer (Panc-1) cell lines. Interestingly, compounds C4 and G4 exhibited the highest cytotoxic activity with average IC50 values of 1.5 µM and 2.8 µM against H-460 and Panc-1, respectively. The virtual docking study was conducted to gain proper understandings of the plausible-binding modes of target compounds within EGFR and COX-2 binding sites. DISCUSSION: The NMR of prepared compounds showed characteristic peaks that confirmed the structure of the target compounds. The synthesized benzoxazolyl scaffold containing compounds showed inhibitory activities for both COXs and EGFR which are consistent with the virtual docking study.
Subject(s)
Cyclooxygenase 2 Inhibitors/pharmacology , Drug Design , Phenols/pharmacology , Plant Extracts/pharmacology , Protein Kinase Inhibitors/pharmacology , Amaranthaceae/chemistry , Cyclooxygenase 2/metabolism , Cyclooxygenase 2 Inhibitors/chemical synthesis , Cyclooxygenase 2 Inhibitors/chemistry , ErbB Receptors/antagonists & inhibitors , ErbB Receptors/metabolism , Humans , Molecular Docking Simulation , Molecular Structure , Phenols/chemical synthesis , Phenols/chemistry , Plant Extracts/chemical synthesis , Plant Extracts/chemistry , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/chemistryABSTRACT
Methylene blue was immobilized onto bentonite (BNT). The modified clay (MB-BNT) was used to extract Hg(2+) at pH 6.0 yielding Hg-MB-BNT. BNT, MB-BNT and Hg-MB-BNT were characterized by X-ray diffractometry, infrared spectra, and elemental and thermogravimetric analyses. MB is suggested to be intercalated into the major phase of BNT; montmorillonite mineral (MMT), lying parallel to the aluminosilicate layers, with a capacity of 36 mequiv./100g. MB-BNT shows good stability in 0.1-1M hydrochloric or nitric acids, ammonium hydroxide, and concentrated Na(+), K(+) or NH(4)(+) chlorides or iodides. It shows good selectivity towards Hg(2+) with an extraction capacity of 37 mequiv./100g in the presence of I(-) giving rise to a ratio of MB/Hg(2+)/I(-) 1:1:3 in the clay phase. Extracted Hg(2+) could be quantitatively recovered by ammonia buffer at pH 8.5. MB-BNT was successfully applied to recover Hg(2+) from spiked natural water and cinnabar mineral samples using the optimum conditions; pH 6.0, time of stirring 10 min and 10 mL of 0.05 M NH(4)Cl/NH(4)OH at pH 8.5 as eluent.
